Physician profile
Mark Lewis
NPI 1134186729
$14,447.84
in general payments reported to CMS, 2019-2025
67 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,349 · 2020: $1,415 · 2021: $959 · 2022: $2,801 · 2023: $2,637 · 2024: $2,292 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,457 · Education: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,456.83 |
| Education | $466.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,491.34 | 2019-2025 | Tagrisso, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $1,160.84 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| Novartis Pharmaceuticals Corporation | $1,030.56 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $856.78 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $790.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $778.95 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $647.63 | 2019-2024 | Tecentriq, Venclexta, Phesgo |
| Astellas Pharma US INC | $542.59 | 2019-2025 | Xospata, Padcev |
| Celgene Corporation | $474.77 | 2019-2024 | Pomalyst, Reblozyl |
| Seagen INC. | $404.84 | 2019-2023 | Tukysa, Padcev, Tivdak |
| Incyte Corporation | $396.80 | 2020-2025 | Jakafi, Zynyz, Monjuvi |
| Glaxosmithkline, LLC. | $385.45 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $315.16 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $313.03 | 2019-2025 | |
| Exelixis INC. | $306.38 | 2019-2024 | Cabometyx |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $286.45 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Lilly USA, LLC | $259.18 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $233.93 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.52 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Kite Pharma, INC. | $204.35 | 2020-2025 | Yescarta |
| Adaptive Biotechnologies Corporation | $199.65 | 2022-2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $189.19 | 2023-2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $168.54 | 2022-2023 | Fotivda |
| Myriad Genetic Laboratories, INC. | $155.59 | 2022-2025 | Myrisk, Precisetumor |
| Teva Pharmaceuticals USA, INC. | $153.86 | 2019-2020 | |
| Advanced Accelerator Applications | $128.55 | 2020 | |
| Caris Mpi, INC. | $128.31 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $125.25 | 2022-2023 | Monoferric |
| Emd Serono, INC. | $105.26 | 2022-2024 | Tepmetko, Bavencio |
| Taiho Oncology, INC. | $104.86 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $99.92 | 2019-2022 | |
| Epizyme, INC. | $95.77 | 2022 | |
| Array Biopharma INC | $95.62 | 2019-2023 | Braftovi, Mektovi |
| Rigel Pharmaceuticals, INC. | $93.79 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Alexion Pharmaceuticals, INC. | $89.15 | 2022-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $71.04 | 2023 | Xpovio |
| Pharmaessentia USA Corporation | $69.57 | 2022-2024 | Besremi |
| Deciphera Pharmaceuticals INC. | $68.92 | 2021-2024 | Qinlock |
| Eisai INC. | $67.54 | 2021-2024 | |
| Verastem, INC. | $66.99 | 2019-2020 | |
| Amgen INC. | $66.93 | 2019-2023 | Kyprolis |
| Janssen Pharmaceuticals, INC | $64.24 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $64.08 | 2021-2023 | Somatuline Depot, Onivyde, Tazverik |
| Beigene USA, INC. | $62.64 | 2023-2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $62.62 | 2025 | |
| Sobi, INC | $55.97 | 2024-2025 | |
| Tempus Ai, INC | $55.96 | 2024 | Xt Cdx |
| Gilead Sciences, INC. | $55.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.00 | 2025 | |
| Servier Pharmaceuticals LLC | $48.01 | 2024 | |
| Kyowa Kirin, INC. | $43.56 | 2022-2024 | Poteligeo |
| Azurity Pharmaceuticals, INC. | $43.55 | 2024-2025 | Vivimusta, Danziten |
| Blue Earth Diagnostics | $40.56 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $36.53 | 2024 | Sylvant |
| Adc Therapeutics America, INC. | $35.84 | 2023 | |
| Coherus Oncology, INC. | $35.60 | 2022 | |
| Stemline Therapeutics INC. | $35.30 | 2024-2025 | Orserdu |
| Foundation Medicine, INC. | $34.02 | 2023 | |
| Tersera Therapeutics LLC | $32.72 | 2023 | Zoladex |
| Fennec Pharmaceuticals, INC. | $24.32 | 2024 | Pedmark |
| Immunogen, INC. | $23.97 | 2023 | Elahere |
| Puma Biotechnology, INC. | $20.89 | 2023 | |
| Beone Medicines USA, INC. | $20.71 | 2025 | Brukinsa |
| Mylan Institutional INC. | $18.79 | 2022 | |
| Iovance Biotherapeutics, INC. | $17.86 | 2025 | Amtagvi |
| Amneal Pharmaceuticals LLC | $17.20 | 2025 | Alymsys |
| Agios Pharmaceuticals, INC. | $16.83 | 2022 |
Drugs and devices associated with these payments
Keytruda $464Venclexta $267Enhertu $245Nubeqa $218Jaypirca $208Lynparza $197Darzalex $196Xofigo $196Talvey $195Verzenio $190Libtayo $189Opdivo $172Padcev $169Kisqali $163Tagrisso $159Clonoseq $156Piqray $146Rybrevant $144Ojjaara $141Cabometyx $136Tukysa $136Ibrance $132Mi Cancer Seek $128Bosulif $127Tecvayli $124Jakafi $117Myrisk $113Adcetris $106Elrexfio $106Reblozyl $104Xtandi $103Imbruvica $101Comirnaty $101Pomalyst $92.51Monoferric $91.38Inqovi $84.58Lonsurf $84.58Ninlaro $84.07Brukinsa $83.35Talzenna $83.01Paxlovid $82.91Welireg $74.46Retevmo $72.31Tecentriq $72.17Xpovio $71.04Jemperli $69.92Alunbrig $69.69Imfinzi $68.49Rezlidhia $66.33Tavalisse $66.33Ultomiris $65.10Zepzelca $62.62Orgovyx $60.81Vonjo $55.97Jevtana $55.41Yescarta $52.31Zejula $49.74Erleada $49.49Pluvicto $45.92Lenvima $44.98Besremi $42.89Xospata $42.58Inlyta $42.15Posluma $40.56Sylvant $36.53Orserdu $35.30Zoladex $32.72Keytruda Qlex $32.45Elahere $30.09Mektovi $28.24Braftovi $28.24Fruzaqla $27.54Gavreto $26.68Tivdak $26.26Poteligeo $25.99Injectafer $25.68Qinlock $25.59Idhifa $25.00Pedmark $24.32Tepmetko $24.18Datroway $23.47Vivimusta $23.14Axumin $23.12Asparlas $23.01Cerdelga $23.00Somatuline Depot $22.78Onivyde $22.78Monjuvi $21.67Zynyz $21.67Tazverik $21.54Tabrecta $20.93Precisetumor $20.86Danziten $20.41Besponsa $19.74Phesgo $19.58Opdualag $19.52Alecensa $18.38Bavencio $18.00Amtagvi $17.86Alymsys $17.20
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.